Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23N7O6.Ca.5H2O |
| Molecular Weight | 587.594 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Ca++].CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)CNC3=C1C(=O)NC(N)=N3
InChI
InChIKey=NVLUUBHWPOLECI-BWDMFOMUSA-L
InChI=1S/C20H25N7O6.Ca.5H2O/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;;;;;;/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);;5*1H2/q;+2;;;;;/p-2/t12-,13-;;;;;;/m0....../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H25N7O6 |
| Molecular Weight | 459.4558 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
For people with MTHFR gene variations, supplementing with the already activated form of folate (5-MTHF/5- METHYLTETRAHYDROFOLATE/LEVOMEFOLIC ACID) is far more effective in providing this form of folate than introducing the pre-converted form to the body through typical folate supplements. L-Methylfolate (5-MTHF) supplements provide the active form of folate naturally present in the body and available for biological action. 5-MTHF—the “active” form of folate that is able to pass the blood brain barrier. However, without a properly functioning methylenetetrahydrofolate reductase, MTHFR this conversion cannot take place and folate is not converted to forms that can cross the blood brain barrier. That is where 5-MTHF supplements come in. Levomefolate calcium is structurally identical to L-5-methyltetrahydrofolate (L-5-methyl-THF), a metabolite of vitamin B9. Mean baseline concentrations of about 15 nmol/L are reached in populations without folate food fortification under normal nutritional conditions. Orally administered levomefolate calcium is absorbed and is incorporated into the body folate pool. Peak plasma concentrations of about 50 nmol/L above baseline are reached within 0.5 – 1.5 hours after single oral administration of 0.451 mg levomefolate calcium. Steady state conditions for total folate in plasma after intake of 0.451 mg levomefolate calcium. In red blood cells, achievement of steady state is delayed due to the long lifespan of red blood cells of about 120 days. Levomefolate calcium is a part of contraceptive tablets: SAFYRA. Safyral is an estrogen/progestin COC (Combined Oral Contraceptive) containing a folate, indicated for use by women to: prevent pregnancy and raise folate levels in women who choose to use an oral contraceptive for contraception. COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
CNS Activity
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | SAFYRAL Approved Use1.1 Oral Contraceptive: Safyral is indicated for use by women to prevent pregnancy. 1.2 Folate Supplementation
Safyral is indicated in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product. Launch Date2010 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
57.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22909145/ |
0.451 mg single, oral dose: 0.451 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
L-5-METHYLTETRAHYDROFOLATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
370 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22909145/ |
0.451 mg single, oral dose: 0.451 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
L-5-METHYLTETRAHYDROFOLATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22909145/ |
0.451 mg single, oral dose: 0.451 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
L-5-METHYLTETRAHYDROFOLATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
44% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22909145/ |
0.451 mg single, oral dose: 0.451 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
L-5-METHYLTETRAHYDROFOLATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. | 2002 Dec |
|
| Does the interaction between maternal folate intake and the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft palate? | 2003 Apr 1 |
|
| Uptake of 5-methyltetrahydrofolate into PC-3 human prostate cancer cells is carrier-mediated. | 2003 Aug |
|
| Reduced folate transport to the CNS in female Rett patients. | 2003 Aug 26 |
|
| Dietary prevention of post-angioplasty restenosis. From illusion and disillusion to pragmatism. | 2003 Dec |
|
| Cobalamin-dependent methionine synthase: probing the role of the axial base in catalysis of methyl transfer between methyltetrahydrofolate and exogenous cob(I)alamin or cob(I)inamide. | 2003 Dec 16 |
|
| Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. | 2003 Dec 18 |
|
| Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. | 2003 Feb |
|
| Affinity extraction combined with stable isotope dilution LC/MS for the determination of 5-methyltetrahydrofolate in human plasma. | 2003 Feb 1 |
|
| Transport of 5-formyltetrahydrofolate into primary cultured rat astrocytes. | 2003 Feb 1 |
|
| Determination of 5-methyltetrahydrofolic acid and folic acid in citrus juices using stable isotope dilution-mass spectrometry. | 2003 Feb 26 |
|
| Transport of 5-formyltetrahydrofolate into primary cultured cerebellar granule cells. | 2003 Feb 7 |
|
| Antisense modulation of the coding or regulatory sequence of the folate receptor (folate binding protein-1) in mouse embryos leads to neural tube defects. | 2003 Jul |
|
| Analysis of the human folate receptor beta gene for an association with neural tube defects. | 2003 Jun |
|
| A mass spectrometric validated high-performance liquid chromatography procedure for the determination of folates in foods. | 2003 Jun 18 |
|
| Residues 45 and 404 in the murine reduced folate carrier may interact to alter carrier binding and mobility. | 2003 Jun 27 |
|
| Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. | 2003 May |
|
| Specific and sensitive quantification of folate vitamers in foods by stable isotope dilution assays using high-performance liquid chromatography-tandem mass spectrometry. | 2003 May |
|
| Characterization of mutations in severe methylenetetrahydrofolate reductase deficiency reveals an FAD-responsive mutation. | 2003 May |
|
| Model studies on the stability of folic acid and 5-methyltetrahydrofolic acid degradation during thermal treatment in combination with high hydrostatic pressure. | 2003 May 21 |
|
| Folate improves endothelial function in patients with coronary heart disease. | 2003 Nov |
|
| Hyperhomocystinemia in children with inflammatory bowel disease. | 2003 Nov |
|
| Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. | 2003 Nov 1 |
|
| Thrombophilia and pregnancy. | 2003 Nov 14 |
|
| Characterization of a pseudogene for murine methylenetetrahydrofolate reductase. | 2003 Oct |
|
| Regulation of S-adenosylmethionine levels in Saccharomyces cerevisiae. | 2003 Oct 31 |
|
| Cerebrospinal fluid pterins and folates in Aicardi-Goutières syndrome: a new phenotype. | 2003 Sep 9 |
|
| Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. | 2004 Apr |
|
| The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men. | 2004 Apr |
|
| Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. | 2004 Apr |
|
| A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. | 2004 Apr 29 |
|
| Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. | 2004 Feb |
|
| Folate, homocysteine, endothelial function and cardiovascular disease. | 2004 Feb |
|
| Determination of folate vitamers in human serum by stable-isotope-dilution tandem mass spectrometry and comparison with radioassay and microbiologic assay. | 2004 Feb |
|
| Solid-phase extraction-electrospray ionization mass spectrometry for the quantification of folate in human plasma or serum. | 2004 Feb 1 |
|
| Comparative study on pressure and temperature stability of 5-methyltetrahydrofolic acid in model systems and in food products. | 2004 Feb 11 |
|
| Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. | 2004 Feb 17 |
|
| Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. | 2004 Jan |
|
| Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. | 2004 Jan 26 |
|
| Placental folate transport and binding are not impaired in pregnancies complicated by fetal growth restriction. | 2004 Jul |
|
| Mutations of the MTHFR gene (428C>T and [458G>T+459C>T]) markedly decrease MTHFR enzyme activity. | 2004 Jun |
|
| Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. | 2004 Mar |
|
| Folic acid rescues nitric oxide-induced neural tube closure defects. | 2004 Mar |
|
| Sodium-dependent methotrexate carrier-1 is expressed in rat kidney: cloning and functional characterization. | 2004 Mar |
|
| 5-Methyltetrahydrofolic acid and folic acid measured in plasma with liquid chromatography tandem mass spectrometry: applications to folate absorption and metabolism. | 2004 Mar 15 |
|
| Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. | 2004 May 10 |
|
| The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. | 2004 May 17 |
|
| Methionine metabolism in plants: chloroplasts are autonomous for de novo methionine synthesis and can import S-adenosylmethionine from the cytosol. | 2004 May 21 |
|
| Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. | 2004 Sep |
|
| Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. | 2004 Sep 15 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:34:03 GMT 2025
by
admin
on
Mon Mar 31 23:34:03 GMT 2025
|
| Record UNII |
JEC017DJGT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
JEC017DJGT
Created by
admin on Mon Mar 31 23:34:03 GMT 2025 , Edited by admin on Mon Mar 31 23:34:03 GMT 2025
|
PRIMARY | |||
|
419563-18-1
Created by
admin on Mon Mar 31 23:34:03 GMT 2025 , Edited by admin on Mon Mar 31 23:34:03 GMT 2025
|
PRIMARY | |||
|
135565054
Created by
admin on Mon Mar 31 23:34:03 GMT 2025 , Edited by admin on Mon Mar 31 23:34:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|